Quarterly ResultMay 5, 2026, 04:14 PM
Trevi Therapeutics Raises $162M, Extends Cash Runway to 2030
AI Summary
Trevi Therapeutics announced its first quarter 2026 financial results, reporting a net loss of $13.2 million. The company successfully completed a follow-on common stock offering in April 2026, generating approximately $162 million in net proceeds, which is expected to extend its cash runway into 2030. This funding is anticipated to support the development of Haduvio through potential FDA approval for IPF-related chronic cough and advance other chronic cough programs. Trevi also provided updates on its clinical development plans, including the initiation of multiple Phase 3 and Phase 2b trials for Haduvio across various chronic cough indications.
Key Highlights
- Completed common stock offering in April 2026, raising ~$162 million in net proceeds.
- Extended cash runway into 2030, funding Haduvio development through potential FDA approval.
- Reported a net loss of $13.2 million for Q1 2026, compared to $10.3 million in Q1 2025.
- Research and development expenses increased to $9.9 million in Q1 2026 from $7.8 million in Q1 2025.
- General and administrative expenses rose to $5.0 million in Q1 2026 from $3.7 million in Q1 2025.
- Plans to initiate the first Phase 3 IPF-related chronic cough trial in Q2 2026.
- Received a European patent for nalbuphine ER for IPF-related chronic cough, expiring in 2039.